Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic adenocarcinoma

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   34220   clinical trials with a EudraCT protocol, of which   5547   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    29 result(s) found for: pancreatic adenocarcinoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000557-61 Sponsor Protocol Number: 2/2007/O/Sper Start Date*: 2007-02-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: PROSPECTIVE RANDOMIZED STUDY ON NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VS. SURGERY ALONE IN PATIENTS WITH RESECTABLE PANCREATIC ADENOCARCINOMA'
    Medical condition: PANCREATIC ADENOCARCINOMA'
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024287-17 Sponsor Protocol Number: PACT-18 Start Date*: 2011-02-03
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Salvage therapy with trabectidin in metastatic pancreatic adenocarcinoma: a single-arm phase II trial.
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051971 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013029-41 Sponsor Protocol Number: PACT-13 Start Date*: 2009-07-07
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplati...
    Medical condition: patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003080-59 Sponsor Protocol Number: GIP-2 Start Date*: 2013-12-19
    Sponsor Name:Azienda Ospedaliero-Universitaria Pisana
    Full Title: PHASE III ITALIAN MULTICENTER STUDY COMPARING THE COMBINATION OF 5-FLUOROURACIL/FOLINIC ACID, OXALIPLATIN AND IRINOTECAN (FOLFOXIRI) VERSUS GEMCITABINE AS ADJUVANT TREATMENT FOR RESECTED PANCREATIC...
    Medical condition: Stage I-III resected pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020979-23 Sponsor Protocol Number: PACT-17 Start Date*: 2010-07-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer.
    Medical condition: pancreas metastatic tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019942-23 Sponsor Protocol Number: PACT-15 Start Date*: 2010-07-02
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Randomized, fase II-III study of peri and post surgery chemiotherapy in removable pancreas carcinoma
    Medical condition: removable pancreas cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033614 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005063-29 Sponsor Protocol Number: GEMOXA001 Start Date*: 2006-01-01
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Induction Chemotherapy with Gemcitabine-Oxaliplatin GEM-OXA followed by concomitant weekly Gemcitabine plus Radiotherapy GEM/RT in Locally Advanced, Unresectable Pancreatic Cancer A Phase II ...
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033633 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000805-11 Sponsor Protocol Number: C26003 Start Date*: 2014-09-09
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)
    Medical condition: Metastatic or Advanced Adenocarcinoma of the Pancreas Expressing Guanylyl Cyclase C (GCC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001408-23 Sponsor Protocol Number: ABI-007-PANC-007 Start Date*: 2015-03-05
    Sponsor Name:Celgene Corporation
    Full Title: NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT)
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004687-30 Sponsor Protocol Number: MM-398-07-03-01 Start Date*: 2012-03-06
    Sponsor Name:Merrimack Pharmaceuticals Inc.
    Full Title: NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who h...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GB (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003866-15 Sponsor Protocol Number: ABI-007-PANC-CA046C Start Date*: 2014-01-24
    Sponsor Name:Celgene Corporation
    Full Title: MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005314-12 Sponsor Protocol Number: WX/60-004 Start Date*: 2007-01-05
    Sponsor Name:Wilex AG
    Full Title: A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to ev...
    Medical condition: Locally advanced, non-resectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004480-20 Sponsor Protocol Number: GS-US-370-1296 Start Date*: 2015-05-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by ...
    Medical condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) CZ (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011305-17 Sponsor Protocol Number: CA046 Start Date*: 2011-08-18
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    Full Title: A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Ongoing) AT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019588-12 Sponsor Protocol Number: Bay86-9766/14905 Start Date*: 2010-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer
    Medical condition: Pancreatic cancer is the eighth most common cause of cancer-related death worldwide, associated with a 5-year survival rate of 5-6%. A vast majority of patients present with incurable advanced dise...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    16.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    16.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Ongoing) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001589-85 Sponsor Protocol Number: D081FC00001 Start Date*: 2014-11-03
    Sponsor Name:Astrazeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...
    Medical condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022757-42 Sponsor Protocol Number: IMM-101-002 Start Date*: 2011-05-17
    Sponsor Name:Immodulon Therapeutics Limited
    Full Title: A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer
    Medical condition: Advanced pancreatic cancer The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and to...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018240-23 Sponsor Protocol Number: CO-101-001 Start Date*: 2010-07-12
    Sponsor Name:Clovis Oncology Inc
    Full Title: A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Ongoing) FR (Ongoing) GB (Ongoing) SE (Completed) DE (Completed) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002844-10 Sponsor Protocol Number: CA209-032 Start Date*: 2013-11-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
    Medical condition: Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovari...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) DE (Ongoing) ES (Ongoing) FI (Ongoing) IT (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003398-91 Sponsor Protocol Number: ABI-007-PANC-003 Start Date*: 2014-05-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
    Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) AT (Ongoing) HU (Ongoing) ES (Ongoing) IT (Ongoing) PT (Ongoing) BE (Ongoing) FI (Ongoing) IE (Ongoing) DK (Ongoing) GB (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Thu Feb 21 06:43:56 GMT 2019 | 30 Churchill Place, Canary Wharf, London E14 5EU     Legal notice
    EMA HMA